Re: Not good for the potential of apabetalone as a Covid-19 therapy
|
|
Resverlogix Corp.
|
Dec 02, 2021 04:34AM
|
Re: Not good for the potential of apabetalone as a Covid-19 therapy
|
10
|
Resverlogix Corp.
|
Nov 30, 2021 11:33AM
|
Re: Not good for the potential of apabetalone as a Covid-19 therapy
|
2
|
Resverlogix Corp.
|
Dec 02, 2021 11:51AM
|
Re: Not good for the potential of apabetalone as a Covid-19 therapy
|
1
|
Resverlogix Corp.
|
Dec 02, 2021 12:05PM
|
Re: Not good for the potential of apabetalone as a Covid-19 therapy
|
1
|
Resverlogix Corp.
|
Nov 30, 2021 05:00PM
|
Re: Not good for the potential of apabetalone as a Covid-19 therapy
|
2
|
Resverlogix Corp.
|
Nov 29, 2021 04:14PM
|
Re: Not good for the potential of apabetalone as a Covid-19 therapy
|
2
|
Resverlogix Corp.
|
Nov 29, 2021 04:36PM
|
Re: Not good for the potential of apabetalone as a Covid-19 therapy
|
3
|
Resverlogix Corp.
|
Dec 01, 2021 02:19PM
|
Re: Not good for the potential of apabetalone as a Covid-19 therapy
|
2
|
Resverlogix Corp.
|
Dec 01, 2021 03:39PM
|
Re: Not much respect
|
1
|
Resverlogix Corp.
|
Dec 14, 2017 04:48PM
|
Re: Not predicting another short attack....
|
5
|
Resverlogix Corp.
|
Aug 23, 2018 02:20PM
|
Re: Not So Fast Mister
|
7
|
Resverlogix Corp.
|
Jun 09, 2018 01:27AM
|
Re: Notice anything different about #11
|
|
Zenith Epigenetics
|
Oct 26, 2023 08:14PM
|
Re: Novartis Phase III study shows Canakinumab reduces MACE events
|
8
|
Resverlogix Corp.
|
Jun 22, 2017 03:12PM
|
Re: Novartis' canakinumab (Ilaris)
|
6
|
Resverlogix Corp.
|
Mar 13, 2018 02:25PM
|
Re: Novavax
|
5
|
Resverlogix Corp.
|
Mar 01, 2023 09:07PM
|
Re: Now recruiting: ZEN-3694 and Talazoparib in Patients With Triple Negative Breast Cancer (TNBC)
|
4
|
Zenith Epigenetics
|
May 06, 2019 06:09PM
|
Re: Now that we're a small cap stock....
|
2
|
Resverlogix Corp.
|
Jul 12, 2018 12:19PM
|
Re: Now that we're a small cap stock....
|
3
|
Resverlogix Corp.
|
Jul 12, 2018 01:32PM
|
Re: NR on phase 1 Kidney Trial
|
3
|
Resverlogix Corp.
|
Jan 23, 2017 12:37PM
|